Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-04-11
2006-04-11
Caputa, Anthony C. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S300000, C530S350000, C514S002600, C424S178100
Reexamination Certificate
active
07026454
ABSTRACT:
The present invention involves a novel neuroendocrine growth factor or marker (“NEM”) identified in cultured prostate cancer cells and conjugates of NEM and a binding agent capable of inhibiting binding of NEM to its receptor.
REFERENCES:
patent: 4826813 (1989-05-01), Huffman et al.
patent: 4876243 (1989-10-01), Marshall et al.
patent: 6251613 (2001-06-01), Kishimoto et al.
Lazar, E. et al. Transforming growth factor alpha: Mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 8(1): 1247-1252, 1988.
Burgess, W.H. et al. J. Cell Biology, 111: 2129-2138, 1990.
Accession No. P55062, Database SwissProt, Walter, L. et al. Mamm. Genome 5: 216-221, 1994.
Accession No. H86387, Database PIR, Mar. 2001.
Accession No. AAB48241, Database Geneseq, in U.S. Patent 6160202, Dec. 2000.
Accession No. Q9MS96, Database SPTREMBL, Whitney, S.M. Oct. 2000.
Lazar, et al., Transforming growth factor alpha: Mutation of aspartic acid 47 and leccine 48 results in different biological activities., Molecular and Cellular Biology, 8 (1), p. 1247-1252, 1988.
Burgess, et al., Possible Dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth facto-1 from its receptor-binding activites by site-directed mutagenesis of a single lysine residue, J. Cell Biology, 111: p. 2129-2138, 1990.
Acession No. P55062, Database SwissProt, Talter, L. et al. Mamm. Genone 5: 216-221, 1994.
Acession No. H86387, Database PIR, Mar. 2001.
Acession No. AAB48241, database Geneseq, In U.S. Patent 6160202, Dec. 2000.
Acession No. Q9MS96, Database SPTREMBL, Whitney, S.M. Oct. 2000.
Cussenot, et al., “Evaluation and clinical valure of neuroendocrine differentiation in human prostatic tumors,” The Prostate Supplement, p. 43-51, 1998.
Cohen, et al., “Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression,” Cancer, p. 1899-1903, 1994.
Huang et al., “Relation between neuroendocrine expression of prostatic carcinoma an prognosis,” Chung. Hua. I. Hsueh. Tsa. Chih, vol. 74, (No. 62), p. 23-25, 1994.
Kadmon et al., “Elevated Plasma chromogranin-a concentrations in prostatic carcinoma,” J. Urol., p. 358-361, 1991.
Schumacher et al., “Identification of d-peptide ligands through mirror-image phage display,” Science, p. 1854, 1996.
Apostolopoulos, et al., “Muc1 cross-reactive gal alpha (1,2) gal antibodies in humans swithc immune responses from cellular to humoral,” Nature Medicine, vol. 4 (No. 3), p. 315-320, 1998.
Samuel, et al., “Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine,” Int. J. Cancer, p. 295-302, 1998.
Foon, et al., “Clinical and Immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen,” Clinical Cancer Research, p. 1267-1276, 1997.
Cole, et al., “Characterization of a sustained-release delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix,” Clinical Cancer Research, p. 867-873, 1997.
Zhang, et al., “Expression of potential targe antigens for immunotherapy on primary and metastatic porstate cancers,” Clincal Cancer Research, p. 295-302, 1998.
Kono et al., “Identification of her2
eu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes,” Int. J. Cancer, p. 202-208, 1998.
Prions met Aptamers, www.cyber-dyne.com/-tom/aptamer.html.
DNA-based vaccine used to fight cancer, www.newswise.com/articels/Cancer.UIC.Html.
Mangoo-Karim, et al., “Renal epithelial cyst formation and enlargement in vitro: dependenc on cAMP,” Proc. Natl. Acad.Sci. USA, p. 6007-6011, 1989.
Cowley, et al., “Elevated c-myc protooncogene expression in autosomal recessive polycystic kidney disease,” Pro. Natl. Acad. Sci. USA, p. 8394-98, 1987.
Grantham et al., “Cyst formation and frowth in autosomal dominatn polycystic kidney disease”, Kidney Int., p. 1145-1152, 1987.
Carone et al., “Basement membrane antigens in renal polycystic disease,” Am. J. Pathol., p. 466-471, 1988.
Grantham et al., “Chemical modification of cell proliferation and fluid secretion in renal cysts,” Kidney Int., p. 1379-1389, 1989.
Davidow et al., “The cystic fibrosis transmemebrane conductance regulatro mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithlium in vitro,” Kidney Int., vol. 50 (No. 1), p. 208-218, 1996.
Yamaguchi et al., “Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly porgressive polycystic kidney disease,” Am. J. Kidney Dis., vol. 30 (No. 5), p. 703-709, 1997.
Carmichal et al., “Molecular biology of vasopressin receptors,” Sem. in Nephrology, vol. 14 (No. 4), p. 341-348, 1994.
Fushimi, Sasaki, et al., “Cloning and expression of apical membrane water channel of rat kidney collecting tubule,” Nature, p. 549-552, 1993.
Yamamura et al., “Characterization of a Novel Aquaretic agen, OPC-31260, as an orall effective, nonpeptide vasopressin V2 receptor antagonist,” British J. Pharm., p. 787-791, 1992.
Laszlo, et al., “Pharmacology and clinical Perspectives of Vasopressin Antagonists”, Pharmacol. Rev., p. 73-108, 1991.
Mah, et al., “Antagonists of arginine-casopressin: experimental and clinical applications,” Drugs Future, p. 1055-1070, 1987.
Manning et al., “Discovery, development, and some uses of vasopresin and oxytocin antagonists,” J. Lab. Clin. Med., p. 617-632, 1989.
Sorensen, et al., “Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease,” J. Int. Med., p. 97-110, 1995.
Serradeil-Le Gal, et al., “Characterization of SR121463A, a highly potent and selective, orally active vasopressin 2 receptor antagonist,” J. Clin. Invest., vol. 98 (No. 12), p. 2729-2738, 1992.
Shimiau K., “Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydrpenic humans,” Kidney International, p. 220-226, 1995.
Ning, et al., “Forskolin stimulates camp production by stimulating vasopressin V2 receptors,” J. Am. Soc. Neph, p. 23, 1997.
Schwartz et al., J. Clin. Invest. 90, 1275, 1992.
Di Sant'Agnesse et al.,, “Neuroendocrine differentiation in prostatic malignancy,” Cancer, ed., vol. 78 (No. 2), p. 357-361, 1996.
Zhau et al.,, “Biomarkers associated with prostate cancer porgression,” Journal of Cellular Biochemistry, Supplement, p. 208-216, 1994.
Hoosein, N.M., “Neuroendocrine and immune mediators in prostate cancer progression,” Frontiers in Biosciene, p. D1274-1285, 1998.
Caputa Anthony C.
Mahoney Joseph A.
Mayer Brown Rowe & Maw LLP
Rebman Christine M.
University of Kansas Medical Center
LandOfFree
Neuroendocrine marker of prostate cancer and method for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neuroendocrine marker of prostate cancer and method for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuroendocrine marker of prostate cancer and method for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3613638